Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 15:7:281-8.
doi: 10.2147/OTT.S56596. eCollection 2014.

The value of radiotherapy in breast cancer patients with isolated ipsilateral supraclavicular lymph node metastasis without distant metastases at diagnosis: a retrospective analysis of Chinese patients

San-Gang Wu  1 , Jia-Yuan Sun  2 , Juan Zhou  3 , Feng-Yan Li  2 , Qin Lin  1 , Huan-Xin Lin  2 , Zhen-Yu He  2
Affiliations

The value of radiotherapy in breast cancer patients with isolated ipsilateral supraclavicular lymph node metastasis without distant metastases at diagnosis: a retrospective analysis of Chinese patients

San-Gang Wu et al. Onco Targets Ther. .

Abstract

Background: The purpose of this study was to investigate the prognosis of ipsilateral supraclavicular lymph node metastasis (ISLM) without evidence of distant metastases at diagnosis in Chinese women with breast cancer and to elucidate the clinical value of adjuvant radiotherapy.

Methods: We performed a retrospective analysis of clinical data for 39 patients with ISLM from breast cancer without distant metastasis at diagnosis. Combined modality therapy, consisting of neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy with or without adjuvant radiotherapy, was offered to the patients.

Results: The patients in this study accounted for 1% of all breast cancer patients treated during the same time period. The median follow-up was 35 months. The 5-year locoregional recurrence-free survival, distant metastasis-free survival, disease-free survival (DFS), and overall survival (OS) were 57.3%, 42.3%, 34.4%, and 46.2%, respectively. Twenty-three patients received postoperative adjuvant radiotherapy. However, there was no significant difference in the 3- and 5-year locoregional recurrence-free survival (P=0.693), ISLM-free recurrence (P=0.964), distant metastasis-free survival (P=0.964), DFS (P=0.234), and OS (P=0.329) rates between the groups of patients who received or did not receive adjuvant radiotherapy (P=0.840). No significant difference in the 3-year locoregional control rate (P=0.900) was found between patients who were treated with adjuvant radiotherapy at ≤50 Gy and >50 Gy. Univariate analysis showed that clinical tumor size stage and age were prognostic factors that impacted DFS and OS.

Conclusion: Combined modality treatment may achieve satisfactory efficacy in Chinese women with ISLM from breast cancer without distant metastasis at the time of diagnosis, suggesting that ISLM might be considered a curable locoregional disease. Adjuvant radiotherapy did not, however, improve the results of these patients.

Keywords: breast cancer; prognosis; radiotherapy; supraclavicular lymph node-metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative survival of patients. Notes: (A) Locoregional recurrence-free survival curve; (B) distant metastasis-free survival curve; (C) disease-free survival curve; and (D) overall survival curve of patients.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. - PubMed
    1. Zhao P, Chen WQ. Annual Report of Cancer Registration in China 2010. Beijing: Military Medical Sciences Press; 2011. [Chinese]
    1. Chen SC, Chen MF, Hwang TL, et al. Prediction of supraclavicular lymph node metastasis in breast carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(3):614–619. - PubMed
    1. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer; 2002.
    1. Hermanek P, Sobin LH, editors. TNM Classification of Malignant Tumours: International Union Against Cancer. 4th ed. New York, NY: Springer; 1987.

LinkOut - more resources